Literature DB >> 30630803

Clinical application and effect of dexmedetomidine in combination with continuous positive airway pressure on one-lung ventilation in lung surgery of elder patients.

Jian Lin1, Jia-Bin Li1, Zhiwei Lu1.   

Abstract

In this study, 126 elder patients who underwent thoracic surgery under general anesthesia were divided into three groups randomly, i.e. dexmedetomidine group, positive ventilation group and combination group. All patients received varying strategies in addition to the one-lung ventilation, and changes in oxidative stress and indicators of inflammation at different time points were observed. In comparison to the dexmedetomidine group and the positive ventilation group, patients in the combination group at T2-3 had lower levels of malonaldehyde, cortisol, C-reaction protein, interleukin-6 (IL-6) and tumor necrosis factor α in serum (p<0.05); one day after surgery, the incidence of complications in lungs of patients in the combination group was significantly lower than those in the dexmedetomidine group and the positive ventilation group (p<0.05). Dexmedetomidine in combination with continuous positive airway pressure can alleviate the oxidative stress and inflammation of lung tissues in one-lung ventilation during the thoracic surgery of elder patients, thus, reducing the incidence of postoperative complications.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30630803

Source DB:  PubMed          Journal:  Pak J Pharm Sci        ISSN: 1011-601X            Impact factor:   0.684


  2 in total

1.  The risk factors for delayed recovery in patients with cardiopulmonary bypass: Why should we care?

Authors:  Baozeng Chen; Mingjing Feng; Chen Sheng; Yinhua Wang; Wenya Cao
Journal:  Medicine (Baltimore)       Date:  2021-03-19       Impact factor: 1.817

Review 2.  Dexmedetomidine attenuates one-lung ventilation associated lung injury by suppressing inflammatory responses: A systematic review and meta-analysis.

Authors:  Yun-Xiao Bai; Jie-Han Zhang; Bing-Cheng Zhao; Ke-Xuan Liu; Yao-Wu Bai
Journal:  Clin Exp Pharmacol Physiol       Date:  2021-06-14       Impact factor: 2.557

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.